- Home
- SIGA vs GBLI Comparison
SIGA vs GBLI Comparison
Compare SIGA & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- GBLI
- Stock Information
- Founded
- SIGA 1995
- GBLI 2016
- Country
- SIGA United States
- GBLI United States
- Employees
- SIGA N/A
- GBLI N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- GBLI Property-Casualty Insurers
- Sector
- SIGA Health Care
- GBLI Finance
- Exchange
- SIGA Nasdaq
- GBLI Nasdaq
- Market Cap
- SIGA 422.9M
- GBLI 484.5M
- IPO Year
- SIGA 1997
- GBLI 2003
- Fundamental
- Price
- SIGA $6.77
- GBLI $30.15
- Analyst Decision
- SIGA
- GBLI
- Analyst Count
- SIGA 0
- GBLI 0
- Target Price
- SIGA N/A
- GBLI N/A
- AVG Volume (30 Days)
- SIGA 382.0K
- GBLI 1.5K
- Earning Date
- SIGA 07-31-2025
- GBLI 08-06-2025
- Dividend Yield
- SIGA 8.70%
- GBLI 4.52%
- EPS Growth
- SIGA N/A
- GBLI N/A
- EPS
- SIGA 0.67
- GBLI 1.99
- Revenue
- SIGA $120,330,310.00
- GBLI $437,447,000.00
- Revenue This Year
- SIGA N/A
- GBLI $7.67
- Revenue Next Year
- SIGA $95.31
- GBLI $7.93
- P/E Ratio
- SIGA $10.28
- GBLI $15.57
- Revenue Growth
- SIGA N/A
- GBLI N/A
- 52 Week Low
- SIGA $4.95
- GBLI $26.94
- 52 Week High
- SIGA $12.83
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- SIGA 61.28
- GBLI 43.28
- Support Level
- SIGA $6.34
- GBLI $30.00
- Resistance Level
- SIGA $7.07
- GBLI $33.25
- Average True Range (ATR)
- SIGA 0.22
- GBLI 0.63
- MACD
- SIGA 0.02
- GBLI -0.26
- Stochastic Oscillator
- SIGA 71.70
- GBLI 3.75
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.